Chitooligosaccharides as a potential immune modulator for reducing particulate matter 10-induced inflammation in pulmonary damage models.

IF 3.3 4区医学 Q4 TOXICOLOGY

Toxicological Research Pub Date : 2025-08-07 eCollection Date: 2025-11-01 DOI:10.1007/s43188-025-00304-0

Chan-Ho Park, Yun-Ho Kim, Ju Myung Kim, Yeo Cho Yoon

{"title":"Chitooligosaccharides as a potential immune modulator for reducing particulate matter 10-induced inflammation in pulmonary damage models.","authors":"Chan-Ho Park, Yun-Ho Kim, Ju Myung Kim, Yeo Cho Yoon","doi":"10.1007/s43188-025-00304-0","DOIUrl":null,"url":null,"abstract":"This study investigated the effects of chitooligosaccharides (COS) on proinflammatory cytokines and nuclear factor-κB (NF-κB) activation in particulate matter 10 (PM10)-induced mice. Results demonstrated that COS treatment significantly reduced proinflammatory cytokines, including interleukin (IL)-6 and IL-1β, particularly in the COS_20 group (20 mg/kg body weight of COS). Lower COS doses correlated with a dose-dependent decrease in proinflammatory cytokine levels and inflammatory cell infiltration in bronchoalveolar lavage fluid and lung tissue. COS treatment increased Th2 cell-related biomarkers (IL-4, IL-5, and IL-13), although these decreased at higher doses. Western blotting analysis revealed that COS suppressed NF-κB activation, particularly in the COS_20 group, suggesting that COS may inhibit IκB degradation, preventing NF-κB translocation to the nucleus and subsequent transcription of proinflammatory genes. These findings indicate that COS effectively mitigates the inflammatory response triggered by PM10 exposure, positioning it as a potential functional health supplement for managing pulmonary inflammation and related disorders.Graphical abstract: Supplementary information: The online version contains supplementary material available at 10.1007/s43188-025-00304-0.","PeriodicalId":23181,"journal":{"name":"Toxicological Research","volume":"41 6","pages":"611-622"},"PeriodicalIF":3.3000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12569294/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43188-025-00304-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"TOXICOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study investigated the effects of chitooligosaccharides (COS) on proinflammatory cytokines and nuclear factor-κB (NF-κB) activation in particulate matter 10 (PM10)-induced mice. Results demonstrated that COS treatment significantly reduced proinflammatory cytokines, including interleukin (IL)-6 and IL-1β, particularly in the COS_20 group (20 mg/kg body weight of COS). Lower COS doses correlated with a dose-dependent decrease in proinflammatory cytokine levels and inflammatory cell infiltration in bronchoalveolar lavage fluid and lung tissue. COS treatment increased Th2 cell-related biomarkers (IL-4, IL-5, and IL-13), although these decreased at higher doses. Western blotting analysis revealed that COS suppressed NF-κB activation, particularly in the COS_20 group, suggesting that COS may inhibit IκB degradation, preventing NF-κB translocation to the nucleus and subsequent transcription of proinflammatory genes. These findings indicate that COS effectively mitigates the inflammatory response triggered by PM10 exposure, positioning it as a potential functional health supplement for managing pulmonary inflammation and related disorders.

Graphical abstract:

Supplementary information: The online version contains supplementary material available at 10.1007/s43188-025-00304-0.

查看原文本刊更多论文

壳寡糖作为一种潜在的免疫调节剂，可减少肺损伤模型中颗粒物质引起的炎症。

本研究探讨壳寡糖（COS）对PM10诱导小鼠促炎细胞因子和核因子-κB （NF-κB）活化的影响。结果表明，COS治疗显著降低了促炎细胞因子，包括白细胞介素(IL)-6和IL-1β，特别是在COS_20组（20 mg/kg体重COS）。低COS剂量与支气管肺泡灌洗液和肺组织中促炎细胞因子水平和炎症细胞浸润的剂量依赖性降低相关。COS治疗增加了Th2细胞相关的生物标志物（IL-4、IL-5和IL-13），尽管这些标志物在高剂量下会降低。Western blotting分析显示，COS抑制了NF-κB的活化，特别是在COS_20组，这表明COS可能抑制了i -κB的降解，阻止了NF-κB易位到细胞核以及随后的促炎基因转录。这些发现表明，COS可有效减轻PM10暴露引发的炎症反应，将其定位为治疗肺部炎症和相关疾病的潜在功能性健康补充剂。图片摘要：补充资料：在线版本包含补充资料，可在10.1007/s43188-025-00304-0获得。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Toxicological Research TOXICOLOGY-

CiteScore

4.20

自引率

4.30%

发文量

期刊介绍： Toxicological Research is the official journal of the Korean Society of Toxicology. The journal covers all areas of Toxicological Research of chemicals, drugs and environmental agents affecting human and animals, which in turn impact public health. The journal’s mission is to disseminate scientific and technical information on diverse areas of toxicological research. Contributions by toxicologists, molecular biologists, geneticists, biochemists, pharmacologists, clinical researchers and epidemiologists with a global view on public health through toxicological research are welcome. Emphasis will be given to articles providing an understanding of the toxicological mechanisms affecting animal, human and public health. In the case of research articles using natural extracts, detailed information with respect to the origin, extraction method, chemical profiles, and characterization of standard compounds to ensure the reproducible pharmacological activity should be provided.